Synapse - Lee Krug

Search Within

Lee M Krug

Results (178)

Response to crizotinib and cabozantinib in stage IV lung adenocarcinoma patients with mutations that cause MET exon 14 skipping

Meeting Abstract

Paik, P. K.; Drilon, A. E.; Yu, H. A.; Krug, L. M.; Rekhtman, N.; Borsu, L.; Ginsberg, M. S.; Berger, M. F.; Ladanyi, M.; Rudin, C. M.
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Phase I study of intra-pleural administration of GL-ONC1, an oncolytic vaccinia virus, in patients with malignant pleural effusion

Meeting Abstract

Krug, L. M.; Zauderer, M. G.; Adusumili, P. S.; McGee, E.; Sepkowitz, K.; Klang, M.; Yu, Y. A.; Scigalla, P.; Rusch, V. W.
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Confirmation of high prevalence of BAP1 inactivation in mesothelioma

Meeting Abstract

Cercek, A.; Zauderer, M. G.; Rimner, A.; Rusch, V. W.; Adusumilli, P. S.; Nash, G. M.; Hmeljak, J.; Ladanyi, M.; Krug, L. M.
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

GDC-0980, a dual PI3K/mTOR inhibitor, selectively inhibits NF2 mutant malignant mesothelioma (MM) cells and inhibits TOR signaling without activating Akt or ERK

Meeting Abstract

Zauderer, M. G.; Moulik, K.; Cooper, J.; Krug, L. M.; Giancotti, F.
Molecular Cancer Therapeutics (2015)

Fulltext@MSK | Save

Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): A phase 3, double-blind, randomised, placebo-controlled trial

Journal Article

Krug, L. M.; Kindler, H. L.; Calvert, H.; Manegold, C.; Tsao, A. S.; Fennell, D.; Öhman, R.; Plummer, R.; Eberhardt, W. E. E.; Fukuoka, K.; more...
Lancet Oncology (2015)

Fulltext@MSK | Save

A multicenter phase II toxicity study of lung-sparing intensity modulated radiation therapy (IMRT) for malignant pleural mesothelioma (MPM)

Meeting Abstract

Zauderer, M. G.; Rimner, A.; Rosenzweig, K.; Wu, A. J. C.; Yorke, E.; Sima, C. S.; Bhattacharjee, N.; Patel, Z.; Gomez, D. R.; Tsao, A. S.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

Phase I trial of the hedgehog (Hh) inhibitor, LDE225, in combination with etoposide and cisplatin (EP) for initial treatment of extensive stage small cell lung cancer (ES-SCLC)

Meeting Abstract

Pietanza, M. C.; Krug, L. M.; Varghese, A. M.; Fleisher, M.; Teitcher, J. B.; Holodny, A.; Sima, C. S.; Litvak, A. M.; Ng, K. K.; Patel, P. R.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

Stage IV large cell neuroendocrine carcinoma (LCNEC) of the lung: Clinicopathologic features, treatment, and survival

Meeting Abstract

Naidoo, J.; Woo, K.; Sima, C. S.; Rekhtman, N.; Thomas, S. B.; Sarkaria, I. S.; Rudin, C. M.; Krug, L. M.; Pietanza, M. C.
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

Prevalence of germline BAP1 mutations in patients with malignant mesothelioma (MM)

Meeting Abstract

Hellmann, M. D.; Borsu, L.; Zehir, A.; Cheng, D. T.; Zha, Z.; Siegel, B.; Rohrer, R. W.; Robson, M. E.; Arnold, A. G.; Fleischut, M. H.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

COMMAND: A phase II randomized, double-blind, placebo-controlled, multicenter study of defactinib as maintenance therapy in subjects with malignant pleural mesothelioma that has not progressed on at least four cycles of pemetrexed/platinum therapy

Meeting Abstract

Fennell, D. A.; Baas, P.; Kindler, H. L.; Krug, L. M.; Nowak, A.; Zauderer, M.; Gralla, R. J.; Keegan, M.; Horobin, J.
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save